# ClinicalTrials.gov record NCT03158090

> PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct03158090-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-03-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03158090-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03158090-lanreotide-v1.json
- Content SHA-256: `b01fac56dfb7e987b316cf8be23545faf0a7dc8b247f9bfc48efcdb3ba587d9d`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03158090 ([`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`](#source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`](#source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03158090 at 2026-07-30T19:42:14.203Z. Its registry update date was 2022-03-16, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`](#source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`](#source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed))

## Sources

<a id="source-ctg-observation-nct03158090-2022-03-16-8e89200a2aed"></a>
- **ClinicalTrials.gov record NCT03158090 · retained source version 2022-03-16:8e89200a2aed158687ac221171612e0f7c7ce0f117c1810dab1b85fc3cc6b6b3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03158090) (`ctg-observation-nct03158090-2022-03-16-8e89200a2aed`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03158090." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03158090-lanreotide-v1.json SHA-256: b01fac56dfb7e987b316cf8be23545faf0a7dc8b247f9bfc48efcdb3ba587d9d.